Superluminal Medicines raised an oversubscribed $60 million Series B to advance an AI-powered GPCR platform and to launch its first clinical trial by year-end. The financing, led by BVF Partners with participation from Deep Track Capital and Perceptive Advisors, supports a selective, biased MC4R agonist targeting rare genetic and hypothalamic obesity. The company’s lead program aims to maximize MC4R pathway signaling while limiting side effects through biased agonism—an approach intended to improve therapeutic index versus less selective melanocortin targeting. With Phase I initiation expected by end of 2026, near-term clinical design and early tolerability data will likely determine investor sentiment. For the obesity and metabolic pipeline, the round reinforces that GPCR-focused, mechanism-specific development remains attractive even as GLP-1-centric revenue models dominate market attention.